A$ 175.27
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Very strong margins and returns
About
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair
Target Price
The average target price of CSL.AX is 294 and suggests 72% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
